---
schema_version: "secwatch.filing_event.v1"
accession: "0001625297-25-000021"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:05:07.567252+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Indivior appoints Joe Ciaffoni as CEO, reduces board to 7, enters amended Oaktree deal

## Summary
- Joe Ciaffoni appointed CEO effective after 2025 AGM but no later than Aug 1, 2025; Mark Crossley remains CEO until then.
- Ciaffoni gets base salary $1,050,000, bonus target 100% of salary, max 200%; on-hire PSUs worth 12x salary (up to 1.575M shares) and RSUs 4x salary (up to 525K shares).
- Board reduced to 7 directors at 2025 AGM; Peter Bains and Jo LeCouilliard not standing for re-election; Robert Schriesheim resigned effective March 2.
- Amended relationship with Oaktree: board to be 8 after search for one new independent director by July 1; Daniel Ninivaggi chairs Nomination Committee.
- Barbara Ryan to succeed Jo LeCouilliard as Chair of Compensation Committee after the 2025 AGM.

## SEC filing metadata
- accession: 0001625297-25-000021
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/indv-20250302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625297-25-000021
- JSON: https://secwatch.observer/filing/0001625297-25-000021.json
- Plain text: https://secwatch.observer/filing/0001625297-25-000021.txt

## Source-grounded claims
- claim_id: 6d26978c1d
  claim: Jo LeCouilliard departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..
  evidence_excerpt: Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm
- claim_id: 7191bb2048
  claim: Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..
  evidence_excerpt: the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm
- claim_id: cab463b328
  claim: Peter Bains departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..
  evidence_excerpt: Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm
- claim_id: cd4cd6aa25
  claim: Robert Schriesheim resigned as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc..
  evidence_excerpt: Robert Schriesheim notified the Board of his resignation therefrom on March 2, 2025 with immediate effect.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.